EP0329184A3
(de)
*
|
1988-02-19 |
1990-05-23 |
Neorx Corporation |
Antimere und antimere Konjugation
|
US6197496B1
(en)
|
1988-06-09 |
2001-03-06 |
Institut Pasteur |
Immunological reagents and diagnostic methods for the detection of human immunodeficiency virus type 2 utilizing multimeric forms of the envelope proteins gp300, p200, and p90/80
|
US5208321A
(en)
*
|
1988-06-09 |
1993-05-04 |
Institut Pasteur |
HIV-2 transmembrane glycoprotein homodimer (GP 80)
|
US5028697A
(en)
*
|
1988-08-08 |
1991-07-02 |
Eli Lilly And Company |
Cytotoxic antibody conjugates of hydrazide derivatized methotrexate analogs via simple organic linkers
|
DK0594803T3
(da)
*
|
1992-03-23 |
2004-03-08 |
Kenneth Naoyuki Matsumura |
Sammensætning til reduktion af bivirkninger af et lægemiddel
|
US5382582A
(en)
*
|
1993-03-26 |
1995-01-17 |
Chan; Carcy L. |
Methotrexate analogs and methods of using same
|
JPH072895A
(ja)
*
|
1993-04-28 |
1995-01-06 |
Eli Lilly & Co |
抗体−薬物複合体
|
AU1140495A
(en)
*
|
1994-01-27 |
1995-08-03 |
Bristol-Myers Squibb Company |
Method for preparing thioether conjugates
|
US5547668A
(en)
*
|
1995-05-05 |
1996-08-20 |
The Board Of Trustees Of The University Of Illinois |
Conjugates of folate anti-effector cell antibodies
|
US5698556A
(en)
*
|
1995-06-07 |
1997-12-16 |
Chan; Carcy L. |
Methotrexate analogs and methods of using same
|
US6451326B2
(en)
|
1996-05-02 |
2002-09-17 |
Burt D. Ensley |
Cosmetic compositions
|
CN1914226B
(zh)
*
|
2003-11-25 |
2012-02-01 |
达纳-法伯癌症研究院有限公司 |
SARS-CoV抗体及其使用方法
|
US7312320B2
(en)
|
2003-12-10 |
2007-12-25 |
Novimmune Sa |
Neutralizing antibodies and methods of use thereof
|
WO2005120567A2
(en)
|
2004-03-03 |
2005-12-22 |
Iq Corporation |
Human anthrax toxin neutralizing monoclonal antibodies and methods of use thereof
|
US20080312201A1
(en)
*
|
2004-09-10 |
2008-12-18 |
Patrick Fogarty |
Reduced Toxicity Methotrexate Formulations and Methods for Using the Same
|
EP1871807B1
(de)
|
2005-02-18 |
2012-11-28 |
Dana-Farber Cancer Institute, Inc. |
Antikörper gegen cxcr4 und anwendungsverfahren dafür
|
BRPI0619036A2
(pt)
|
2005-11-28 |
2011-09-20 |
Vernon D Rowe |
composições úteis para reduzir a nefrotoxicidade, e uso destas
|
WO2007065027A2
(en)
*
|
2005-12-02 |
2007-06-07 |
Dana Farber Cancer Institute |
Carbonic anhydrase ix (g250) antibodies and methods of use thereof
|
JP2010526868A
(ja)
|
2007-05-14 |
2010-08-05 |
ノビミューン エスアー |
改変されたエフェクター機能を有するFc受容体結合ポリペプチド
|
EP3333187B1
(de)
|
2007-12-06 |
2022-06-22 |
Dana-Farber Cancer Institute, Inc. |
Antikörper gegen influenzavirus und verfahren zur verwendung davon
|
WO2009086514A1
(en)
|
2007-12-28 |
2009-07-09 |
Dana-Farber Cancer Institute, Inc. |
Humanized monoclonal antibodies and methods of use
|
AU2009223453B2
(en)
|
2008-03-03 |
2014-05-01 |
Tosk, Inc. |
Methotrexate adjuvants to reduce toxicity and methods for using the same
|
WO2010027818A2
(en)
|
2008-08-25 |
2010-03-11 |
Dana-Farber Cancer Institute, Inc. |
Conserved hemagglutinin epitope, antibodies to the epitope, and methods of use
|
MX348013B
(es)
|
2009-05-05 |
2017-05-23 |
Novimmune Sa |
Anticuerpos anti il-17f y metodos de uso de los mismos.
|
EP2440922B1
(de)
|
2009-06-12 |
2016-08-10 |
Vaccine Technologies, Incorporated |
Verfahren für diagnostische tests zur messung einer zellvermittelten immunantwort
|
ES2648885T3
(es)
|
2010-06-02 |
2018-01-08 |
Dana-Farber Cancer Institute, Inc. |
Anticuerpos monoclonales humanizados y métodos de uso
|
EP2706991B1
(de)
|
2011-05-11 |
2021-03-24 |
Children's Medical Center Corporation |
Immunogene zusammensetzung mit mehreren antigenen sowie verfahren dafür und verwendungen davon
|
EP2710042A2
(de)
|
2011-05-16 |
2014-03-26 |
Fabion Pharmaceuticals, Inc. |
Multispezifische fab-fusionsproteine und verwendungsverfahren dafür
|
PE20141908A1
(es)
|
2012-02-06 |
2014-12-21 |
Inhibrx Llc |
Anticuerpos cd47 y metodos de uso los mismos
|
AU2013237929B2
(en)
|
2012-03-29 |
2017-09-14 |
Novimmune S.A. |
Anti-TLR4 antibodies and uses thereof
|
JP2015516813A
(ja)
|
2012-04-27 |
2015-06-18 |
シトムクス セラピューティクス,インコーポレイティド |
上皮成長因子受容体を結合する活性化可能抗体及びその使用方法
|
AU2013256010B2
(en)
|
2012-05-04 |
2018-01-04 |
Dana-Farber Cancer Institute, Inc. |
Affinity matured anti-CCR4 humanized monoclonal antibodies and methods of use
|
US9856314B2
(en)
|
2012-06-22 |
2018-01-02 |
Cytomx Therapeutics, Inc. |
Activatable antibodies having non-binding steric moieties and methods of using the same
|
CA2877886A1
(en)
|
2012-06-25 |
2014-01-03 |
The Brigham And Women's Hospital, Inc. |
Targeted therapeutics comprising heparin binding protein
|
MX370848B
(es)
|
2012-10-04 |
2020-01-08 |
Dana Farber Cancer Inst Inc |
Anticuerpos monoclonales humanos anti-pd-l1 y métodos de uso.
|
CA2892585C
(en)
|
2012-12-03 |
2022-07-05 |
Novimmune S.A. |
Anti-cd47 antibodies and methods of use thereof
|
KR102170196B1
(ko)
|
2013-02-06 |
2020-10-26 |
인히브릭스, 인크. |
비-혈소판 및 비-적혈구 세포 격감성 cd47 항체 및 이를 이용하는 방법
|
BR112015021341B1
(pt)
|
2013-03-15 |
2023-03-28 |
Dana-Farber Cancer Institute Inc. |
Anticorpos monoclonais humanizados isolados neutralizantes de flavivírus e usos terapêuticos dos mesmos
|
RU2015156888A
(ru)
|
2013-06-04 |
2017-07-14 |
Сайтомкс Терапьютикс, Инк. |
Композиции и методы конъюгирования активируемых антител
|
DK3024851T3
(en)
|
2013-07-25 |
2018-08-06 |
Cytomx Therapeutics Inc |
MULTI-SPECIFIC ANTIBODIES, MULTI-SPECIFICALLY ACTIVABLE ANTIBODIES, AND METHODS FOR USING IT
|
US10077304B2
(en)
|
2013-08-14 |
2018-09-18 |
The Governing Council Of The University Of Toronto |
Antibodies against frizzled receptor
|
NZ718283A
(en)
|
2013-09-25 |
2022-05-27 |
Cytomx Therapeutics Inc |
Matrix metalloproteinase substrates and other cleavable moieties and methods of use thereof
|
US9540440B2
(en)
|
2013-10-30 |
2017-01-10 |
Cytomx Therapeutics, Inc. |
Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
|
US9737623B2
(en)
|
2013-12-11 |
2017-08-22 |
Cytomx Therapeutics, Inc. |
Antibodies that bind activatable antibodies and methods of use thereof
|
AU2015210862B2
(en)
|
2014-01-31 |
2020-04-23 |
Cytomx Therapeutics, Inc |
Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use thereof
|
EP4043489A1
(de)
|
2014-03-19 |
2022-08-17 |
Dana-Farber Cancer Institute, Inc. |
Immungenetische beschränkung der elazitation von antikörpern
|
KR20160145813A
(ko)
|
2014-04-25 |
2016-12-20 |
다나-파버 캔서 인스티튜트 인크. |
중동 호흡기 증후군 코로나바이러스 중화 항체 및 이의 사용 방법
|
TWI695011B
(zh)
|
2014-06-18 |
2020-06-01 |
美商梅爾莎納醫療公司 |
抗her2表位之單株抗體及其使用之方法
|
AU2015292406B2
(en)
|
2014-07-25 |
2021-03-11 |
Cytomx Therapeutics, Inc |
Anti-CD3 antibodies, activatable anti-CD3 antibodies, multispecific anti-CD3 antibodies, multispecific activatable anti-CD3 antibodies, and methods of using the same
|
CN107250159A
(zh)
|
2014-10-03 |
2017-10-13 |
达纳-法伯癌症研究所公司 |
糖皮质激素诱导的肿瘤坏死因子受体(gitr)抗体及其使用方法
|
EP3699196A1
(de)
|
2014-10-06 |
2020-08-26 |
Dana Farber Cancer Institute, Inc. |
Humanisierte antikörper des cc-chemokin-rezeptors 4 (ccr4) und verfahren zur verwendung davon
|
MA41374A
(fr)
|
2015-01-20 |
2017-11-28 |
Cytomx Therapeutics Inc |
Substrats clivables par métalloprotéase matricielle et clivables par sérine protéase et procédés d'utilisation de ceux-ci
|
CA2978942A1
(en)
|
2015-03-13 |
2016-09-22 |
Cytomx Therapeutics, Inc. |
Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof
|
KR102668588B1
(ko)
|
2015-04-08 |
2024-05-22 |
다나-파버 캔서 인스티튜트 인크. |
인간화된 인플루엔자 모노클로날 항체 및 그의 사용 방법
|
JP6956639B2
(ja)
|
2015-05-01 |
2021-11-02 |
デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド |
抗ccr4抗体を用いてサイトカイン発現を媒介する方法
|
CN107922490A
(zh)
|
2015-05-04 |
2018-04-17 |
西托姆克斯治疗公司 |
抗ITGa3抗体、可活化抗ITGa3抗体及其使用方法
|
CN108026170B
(zh)
|
2015-05-04 |
2022-03-01 |
西托姆克斯治疗公司 |
抗cd71抗体、可活化抗cd71抗体及其使用方法
|
US10745481B2
(en)
|
2015-05-04 |
2020-08-18 |
Cytomx Therapeutics, Inc. |
Anti-CD166 antibodies, activatable anti-CD166 antibodies, and methods of use thereof
|
CN108368170B
(zh)
|
2015-07-13 |
2022-04-15 |
西托姆克斯治疗公司 |
抗pd-1抗体、可活化抗pd-1抗体及其使用方法
|
US10870701B2
(en)
|
2016-03-15 |
2020-12-22 |
Generon (Shanghai) Corporation Ltd. |
Multispecific fab fusion proteins and use thereof
|
US10947317B2
(en)
|
2016-03-15 |
2021-03-16 |
Mersana Therapeutics, Inc. |
NaPi2b-targeted antibody-drug conjugates and methods of use thereof
|
RU2019104896A
(ru)
|
2016-07-22 |
2020-08-24 |
Дана-Фарбер Кэнсер Инститьют, Инк. |
Антитела к глюкокортикоид-индуцированному рецептору фактора некроза опухоли (gitr) и способы их использования
|
WO2018045379A1
(en)
|
2016-09-02 |
2018-03-08 |
Dana-Farber Cancer Institute, Inc. |
Composition and methods of treating b cell disorders
|
MX2019002696A
(es)
|
2016-09-06 |
2019-09-27 |
Dana Farber Cancer Inst Inc |
Metodos para tratar o prevenir una infeccion del virus del zika.
|
WO2018049261A1
(en)
|
2016-09-09 |
2018-03-15 |
Icellhealth Consulting Llc |
Oncolytic virus expressing immune checkpoint modulators
|
EP3535299A1
(de)
|
2016-11-04 |
2019-09-11 |
Novimmune S.A. |
Anti-cd19-antikörper und verfahren zur verwendung davon
|
TW201834697A
(zh)
|
2017-02-28 |
2018-10-01 |
美商梅爾莎納醫療公司 |
Her2標靶抗體-藥物結合物之組合療法
|
BR112019018541A2
(pt)
|
2017-03-09 |
2020-04-14 |
Cytomx Therapeutics Inc |
anticorpos cd147, anticorpos cd147 ativáveis e métodos de produção e uso dos mesmos
|
AU2018272311A1
(en)
|
2017-05-26 |
2019-12-19 |
Novimmune Sa |
Anti-CD47 x anti-mesothelin antibodies and methods of use thereof
|
EP3630838A1
(de)
|
2017-06-01 |
2020-04-08 |
CytomX Therapeutics, Inc. |
Aktivierbare anti-pdl1-antikörper und verfahren zur verwendung davon
|
US20210025877A1
(en)
|
2017-07-20 |
2021-01-28 |
CytomX Therapeutices, Inc. |
Methods of qualitatively and/or quantitatively analyzing properties of activatable antibodies and uses thereof
|
BR112020004231A2
(pt)
|
2017-08-30 |
2020-09-08 |
Cytomx Therapeutics, Inc. |
anticorpos anti-cd166 ativáveis e métodos de uso dos mesmos
|
HUE054037T2
(hu)
|
2017-10-14 |
2021-08-30 |
Abbvie Inc |
CD71 elleni, aktiválható antitest hatóanyag konjugátumok és eljárások alkalmazásukra
|
SG11202002384VA
(en)
|
2017-10-14 |
2020-04-29 |
Cytomx Therapeutics Inc |
Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof
|
EP3762420A1
(de)
|
2018-03-09 |
2021-01-13 |
CytomX Therapeutics, Inc. |
Aktivierbare cd147-antikörper und verfahren zur herstellung und verwendung davon
|
US20220023439A1
(en)
|
2018-11-02 |
2022-01-27 |
Cytomx Therapeutics, Inc. |
Activatable anti-cd166 antibodies and methods of use thereof
|
SG11202105476XA
(en)
|
2018-12-06 |
2021-06-29 |
Cytomx Therapeutics Inc |
Matrix metalloprotease-cleavable and serine or cysteine protease-cleavable substrates and methods of use thereof
|
CN113874394B
(zh)
|
2019-02-20 |
2024-01-19 |
和铂抗体有限公司 |
抗体
|
JP2022523200A
(ja)
|
2019-02-26 |
2022-04-21 |
シートムエックス セラピューティクス,インコーポレイテッド |
活性化可能な免疫チェックポイント阻害剤とコンジュゲートされた活性化可能な抗体の組み合わせ療法
|
CN114650844A
(zh)
|
2019-09-23 |
2022-06-21 |
西托姆克斯治疗公司 |
抗cd47抗体、可活化抗cd47抗体及其使用方法
|
US20230057263A1
(en)
|
2020-01-06 |
2023-02-23 |
Cytomx Therapeutics, Inc. |
Single-and multi-chain polypeptides that bind specifically to cd3 epsilon
|
GB202003632D0
(en)
|
2020-03-12 |
2020-04-29 |
Harbour Antibodies Bv |
SARS-Cov-2 (SARS2, COVID-19) antibodies
|
CN115667523A
(zh)
|
2020-04-10 |
2023-01-31 |
西托姆克斯治疗公司 |
可活化细胞因子构建体和相关组合物以及方法
|
WO2022006562A1
(en)
|
2020-07-03 |
2022-01-06 |
Dana-Farber Cancer Institute, Inc. |
Multispecific coronavirus antibodies
|
TW202304958A
(zh)
|
2021-03-16 |
2023-02-01 |
美商Cytomx生物製藥公司 |
經遮蔽之可活化之細胞介素構築體及相關之組成物及方法
|
WO2022200389A1
(en)
|
2021-03-22 |
2022-09-29 |
Novimmune S.A. |
Bispecific antibodies targeting cd47 and pd-l1 and methods of use thereof
|
WO2022200387A1
(en)
|
2021-03-22 |
2022-09-29 |
Novimmune S.A. |
Bispecific antibodies targeting cd47 and pd-l1 and methods of use thereof
|
EP4334354A1
(de)
|
2021-05-06 |
2024-03-13 |
Dana-Farber Cancer Institute, Inc. |
Antikörper gegen alk und verfahren zur verwendung davon
|
WO2023036982A1
(en)
|
2021-09-10 |
2023-03-16 |
Harbour Antibodies Bv |
Anti-sars2-s antibodies
|
GB202112935D0
(en)
|
2021-09-10 |
2021-10-27 |
Harbour Antibodies Bv |
Sars-cov-2 (sars2, covid-19) heavy chain only antibodies
|
TW202334187A
(zh)
|
2021-10-08 |
2023-09-01 |
美商Cytomx生物製藥公司 |
可活化細胞激素構築體及相關組成物與方法
|
KR20240099172A
(ko)
|
2021-10-08 |
2024-06-28 |
싸이톰스 테라퓨틱스, 인크. |
활성화 가능한 사이토카인 작제물 및 조합 방법
|
AR127343A1
(es)
|
2021-10-13 |
2024-01-31 |
Cytomx Therapeutics Inc |
Construcciones de citoquinas activables triméricas y composiciones y métodos relacionados
|
AU2022383057A1
(en)
|
2021-11-05 |
2024-05-16 |
Abviro Llc |
Human broadly crossreactive influenza monoclonal antibodies and methods of use thereof
|
AU2022396272A1
(en)
|
2021-11-24 |
2024-06-06 |
Dana-Farber Cancer Institute, Inc. |
Antibodies against ctla-4 and methods of use thereof
|
WO2023114544A1
(en)
|
2021-12-17 |
2023-06-22 |
Dana-Farber Cancer Institute, Inc. |
Antibodies and uses thereof
|
CA3241407A1
(en)
|
2021-12-17 |
2023-06-22 |
Dana-Farber Cancer Institute, Inc. |
Platform for antibody discovery
|
WO2023150552A1
(en)
|
2022-02-04 |
2023-08-10 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for treatment of neurological disorders
|
WO2023178357A1
(en)
|
2022-03-18 |
2023-09-21 |
Evolveimmune Therapeutics, Inc. |
Bispecific antibody fusion molecules and methods of use thereof
|
WO2023183923A1
(en)
|
2022-03-25 |
2023-09-28 |
Cytomx Therapeutics, Inc. |
Activatable dual-anchored masked molecules and methods of use thereof
|
WO2023192973A1
(en)
|
2022-04-01 |
2023-10-05 |
Cytomx Therapeutics, Inc. |
Activatable multispecific molecules and methods of use thereof
|
WO2023192606A2
(en)
|
2022-04-01 |
2023-10-05 |
Cytomx Therapeutics, Inc. |
Cd3-binding proteins and methods of use thereof
|
WO2024030845A1
(en)
|
2022-08-01 |
2024-02-08 |
Cytomx Therapeutics, Inc. |
Protease-cleavable moieties and methods of use thereof
|
WO2024030847A1
(en)
|
2022-08-01 |
2024-02-08 |
Cytomx Therapeutics, Inc. |
Protease-cleavable moieties and methods of use thereof
|
WO2024030858A1
(en)
|
2022-08-01 |
2024-02-08 |
Cytomx Therapeutics, Inc. |
Protease-cleavable substrates and methods of use thereof
|
WO2024030843A1
(en)
|
2022-08-01 |
2024-02-08 |
Cytomx Therapeutics, Inc. |
Protease-cleavable moieties and methods of use thereof
|
WO2024030850A1
(en)
|
2022-08-01 |
2024-02-08 |
Cytomx Therapeutics, Inc. |
Protease-cleavable substrates and methods of use thereof
|
WO2024039672A2
(en)
|
2022-08-15 |
2024-02-22 |
Dana-Farber Cancer Institute, Inc. |
Antibodies against msln and methods of use thereof
|
WO2024039670A1
(en)
|
2022-08-15 |
2024-02-22 |
Dana-Farber Cancer Institute, Inc. |
Antibodies against cldn4 and methods of use thereof
|
WO2024084052A1
(en)
|
2022-10-21 |
2024-04-25 |
Novimmune Sa |
Pd-l1xcd28 bispecific antibodies for immune checkpoint-dependent t cell activation
|